Pharma & Biotech Mergers & Acquisitions News
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Generics
A confluence of factors is creating a conducive environment for mergers and acquisitions (M&As) to pick up pace in India. 23 October 2023
article
Featuring in last week’s news, Swiss firm MoonLake Immunotherapies announced new Phase II MIRA study data showing that its antibody sonelokimab further improved response rate in hidradenitis suppurativa. Last Tuesday, Monte Rosa Therapeutics announced a potentially $2 billion licensing deal with Roche for its molecular glue degrader-based medicine, and also released early-stage results for its cancer candidate MRT-2359. Japan’s Daiichi Sankyo signed a mega bucks deal with US pharma giant Merck & Co for three antibody drug conjugates (ADCs) that could potentially be worth $22 billion. On the M&A front, Eli Lilly agreed to acquire French pre-clinical stage biotech Mablink Biosciences and its lead candidate MBK-103 for an undisclosed amount. 22 October 2023
Biotechnology
The European Commission has unconditionally approved the proposed $43 billion acquisition of US biotech Seagen by pharma giant Pfizer, under the EU Merger Regulation. 21 October 2023
Biotechnology
French pre-clinical biotech Mablink Biosciences has confirmed earlier rumors that it has agreed to a takeover bid from acquisition-hungry US pharma major Eli Lilly. 19 October 2023
Biotechnology
Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, has emerged from stealth. 17 October 2023
Biotechnology
ZQ Capital Management has made an offer for UK-based Allergy Therapeutics, as required by takeover rules. 16 October 2023
Biotechnology
Featuring on the M&A front last week, US pharma major Bristol Myers Squibb revealed that it has reached agreement to acquire KRAS inhibitor company Mirati Therapeutics, and its lung cancer drug Krazati, for $4.8 billion. Among research news, Akero Therapeutics presented new Phase IIb results for its non-alcoholic steatohepatitis candidate, efruxifermin, which failed to impress investors. Regulatory developments included Supernus Pharmaceuticals resubmitting its new drug application (NDA) to the US Food and Drug Administration (FDA) for SPN-830 amomorphine infusion device for CNS diseases. The FDA revised its Manual of Policies and Procedures for generic drug submissions. Also, on Friday, the FDA approved US pharma giant Pfizer’s Velsipity (etrasimod) for the treatment of ulcerative colitis. 15 October 2023
Biotechnology
Swedish biotech Promore Pharma will soon run out of money, and has begun liquidation proceedings, the company announced. 12 October 2023
Pharmaceutical
Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabian Public Investment Fund (PIF), says it has successfully completed its acquisition of a 70% stake in SaudiBio. 11 October 2023
Biotechnology
M&A activity last week featured US pharma major Eli Lilly last Tuesday announcing it was acquiring radioligand company POINT Biopharma for around $1.4 billion, along with its lead candidate PNT2002. On the regulatory front, Japan’s Takeda last Monday revealed that, following discussions with the US Food and Drug Administration (FDA), it is voluntarily withdrawing its lung cancer drug Exkivity from the market, as the confirmatory trial to convert accelerated approval to regular authorization had failed. Also, last Thursday, an FDA advisory committee came up with a negative vote on US biotech giant Amgen’s Lumakras. Also of note, last Wednesday Ionis Pharmaceuticals held an R&D investor day, when it outlined its pipeline and progress of investigational drugs including Waylivra and olezarsen. 8 October 2023
Biotechnology
US biotech giant Amgen has at last completed its acquisition of Ireland-headquartered Horizon Therapeutics for $116.50 per share in cash, representing a transaction equity value of around $27.8 billion, that was announced in December last year. 7 October 2023
Pharmaceutical
Pharma's biggest companies were inactive during September's M&A market. 6 October 2023
Biotechnology
US pharma major AbbVie has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson's disease (PD). 6 October 2023
Biotechnology
Shares of US and UK-based gene therapy company Orchard Therapeutics almost doubled to $16.03 in pre-market activity today, on the news that it has received a takeover offer from mid-size Japanese drugmaker Kyowa Kirin. 5 October 2023
Generics
USA-based drugmaker Viatris has announced a series of divestitures as part of a strategy to narrow the company’s focus. 3 October 2023
Pharmaceutical
Shares US radiopharmaceuticals firm POINT Biopharma Global shot up 84% to $12.31 in pre-market activity, on the news of a takeover bid from Eli Lilly. 3 October 2023
Biotechnology
Today, Boston, USA-based Clade Therapeutics announced the acquisition of Gadeta, a Netherlands-based cell therapy company developing innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients. 2 October 2023
Biotechnology
Among important research news last week, US clinical-stage biotech Immunovant leapt 80% after it released early data on its IMVT-1402 autoimmune disease candidate. Also, Ionis Pharmaceuticals announced positive Phase III results for its investigational rare disease drug olezarsen. Troubled US biotech Intercept Pharmaceuticals has accepted an around $800 million takeover bid from Italian privately-owned drugmaker Alfasigma. Last week saw pharma major AbbVie pull out of another licensing collaboration, this time with Caribou Biosciences on two programs on allogenic CAR-T products. And, on the regulatory front, the US Food and Drug Administration (FDA) finally approved Amicus Therapeutics’ Pompe disease combination of Pombiliti plus Opfolda. 1 October 2023
Pharmaceutical
US financial services company Morningstar has published its Biopharma Pipeline Report which provides a five-year outlook on key trends in the space, as well as an in-depth review of pipelines and major therapeutic areas. 29 September 2023
Biotechnology
Italy-based Alfasigma has reached an agreement to acquire US biopharma Intercept Pharmaceuticals. 27 September 2023
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Biotechnology
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio. 26 October 2024
Biotechnology
Mumbai-based Mankind Pharma has completed its acquisition of Bharat Serums and Vaccines (BSV), adding to its portfolio in the women’s health and fertility market. 24 October 2024
Biotechnology
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases. 24 October 2024
Biotechnology
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co 23 October 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
Last week’s significant news included Denmark-based CNS drugmaker Lundbeck reaching agreement to acquire US firm Longboard Pharmaceuticals, along with its bexicaserin, for $2.6 billion. Also, US pharma giant Pfizer entered into a deal with TRIANA Biomedicines to develop molecular glue degraders. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Novocure’s key product Optune Lua for lung cancer patients. Also, German biotech BioNTech and its US partner OncoC4 received a partial clinical hold from the FDA on the Phase III trial of gotistobart in lung cancer. The European Medicines Agency’s human health committee, CHMP, Reaffirmed its non-approval of PTC Therapeutic’s Translarna. 20 October 2024
Biotechnology
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
Biotechnology
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals. 15 October 2024
Biotechnology
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze